SCHEMBL16792009

SCHEMBL16792009

OB(O)c1cnc(N2CCNCC2)nc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 1/20 0.53
TAAR1 Q96RJ0 1/20 0.49
HRH1 P35367 1/20 0.42
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CASP1 P29466 3/20 0.41
CASP4 P49662 1/20 0.41
CASP5 P51878 1/20 0.41
HDAC6 Q9UBN7 2/20 0.39
TSHR P16473 3/20 0.39
CYP3A4 P08684 2/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP1A2 P05177 2/20 0.38
CASP7 P55210 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007187 0.82 ALDH1A1 (0.38) ALDH1A1KDM4EUSP2SMN1; SMN2HDAC6
SCHEMBL3946301 0.82 ALDH1A1 (0.41) ALDH1A1HRH1SMN1; SMN2CASP1CASP4
SCHEMBL3945544 0.81 POLB (0.42) ALDH1A1USP2SMN1; SMN2TDP1HDAC6
SCHEMBL15416439 0.79 PIK3CA (0.37) ALDH1A1KDM4ETAAR1SMN1; SMN2CASP1
SCHEMBL2739054 0.79 ALDH1A1 (0.59) ALDH1A1KDM4ETAAR1HRH1USP2
SCHEMBL16909896 0.78 KDM4E (0.33) ALDH1A1KDM4ETAAR1HRH1
SCHEMBL15330361 0.78 HTR3A (0.46) ALDH1A1USP2TDP1CASP1HDAC6
SCHEMBL16793545 0.78 PTPN11 (0.38) ALDH1A1HSD17B10
SCHEMBL5525017 0.78 POLB (0.57) ALDH1A1KDM4EUSP2HDAC6TSHR
SCHEMBL723901 0.77 PLD1 (0.49) ALDH1A1KDM4EUSP2TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-9957255-B2 Benzotriazole derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-05-01 US disclosed
EP-3080107-A1 BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
US-20160297799-A1 Benzotriazole Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2016-10-13 US disclosed
WO-2015086508-A1 BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297799-A1 Benzotriazole Derivatives as Modulators of TNF Activity TNF, NFKBIA, TNFRSF1A ALDH1A1 1023/4885KDM4E 4091/4885TAAR1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.